Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters

Xenobiotica

Volumn 42, Issue 7, 2012, Pages 603-613

  Kwak, Eun Young ^a   Shim, Won Sik ^b   Chang, Ji Eun ^a   Chong, Saeho ^a   Kim, Dae Duk ^a   Chung, Suk Jae ^a   Shim, Chang Koo ^a  

^a Seoul National University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Amino acid transporters; Enhanced accumulation; Ester prodrug; SN 38

Indexed keywords

AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; FIRTECAN; IRINOTECAN; PRODRUG; VALINE;

ARTICLE; CANCER CELL; CELL MEMBRANE PERMEABILITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACCUMULATION; EFFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE;

EID: 84861843891     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.646339     Document Type: Article

References (47)

1. Adeyinka A, Emberley E, Niu Y, Snell L, Murphy LC, Sowter H, Wykoff CC, Harris AL, Watson PH. (2002). Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Cancer Res 8:3788-3795.
2. Anand BS, Katragadda S, Nashed YE, Mitra AK. (2004). Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Curr Eye Res 29:153-166.
3. Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M. (1995). Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385.
4. Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ. (1998). Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 250:246-251.
5. Capdeville R, Buchdunger E, Zimmermann J, Matter A. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502.
6. Chan HS, Thorner PS, Haddad G, Ling V. (1990). Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704.
7. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V. (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608-1614.
8. de Miranda P, Blum MR. (1983). Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 12 Suppl B:29-37.
9. Deininger M, Buchdunger E, Druker BJ. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653.
10. Fuchs BC, Bode BP. (2005). Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15:254-266.
11. Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. (1998). Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 246:470-475.
12. Laco GS, Collins JR, Luke BT, Kroth H, Sayer JM, Jerina DM, Pommier Y. (2002). Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry 41:1428-1435.
13. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R. (1993). Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81:2394-2398.
14. Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ. (1999). Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 289:448-454.
15. Gupta N, Prasad PD, Ghamande S, Moore-Martin P, Herdman AV, Martindale RG, Podolsky R, Mager S, Ganapathy ME, Ganapathy V. (2006). Up-regulation of the amino acid transporter ATB0,+ (SLC6A14) in carcinoma of the cervix. Gynecol Oncol 100:8-13.
16. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadée W, Amidon GL. (1998). 5?-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 15:1154-1159.
17. Han HK, Oh DM, Amidon GL. (1998). Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res 15:1382-1386.
18. Hatanaka T, Haramura M, Fei YJ, Miyauchi S, Bridges CC, Ganapathy PS, Smith SB, Ganapathy V, Ganapathy ME. (2004). Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308:1138-1147.
19. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. (1999). Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535.
20. Hyde R, Taylor PM, Hundal HS. (2003). Amino acid transporters: roles in amino acid sensing and signalling in animal cells. Biochem J 373:1-18.
21. Jung D, Dorr A. (1999). Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 39:800-804.
22. Katragadda S, Jain R, Kwatra D, Hariharan S, Mitra AK. (2008). Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. Int J Pharm 362:93-101.
23. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. (1997). Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistanceassociated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547.
24. Landowski CP, Song X, Lorenzi PL, Hilfinger JM, Amidon GL. (2005). Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res 22:1510-1518.
25. Landowski CP, Vig BS, Song X, Amidon GL. (2005). Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther 4:659-667.
26. Lerchen HG. (1999). Camptothecin antitumor agents. IDrugs 2:896-906.
27. Li F, Hong L, Mau CI, Chan R, Hendricks T, Dvorak C, Yee C, Harris J, Alfredson T. (2006). Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J Pharm Sci 95:1318-1325.
28. Li F, Maag H, Alfredson T. (2008). Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 97:1109-1134.
29. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE. (2000). The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 (Pt 11):2011-2021.
30. Majumdar S, Hingorani T, Srirangam R, Gadepalli RS, Rimoldi JM, Repka M.A. (2009). Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Pharm Res 26:1261-1269.
31. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. (1999). Overexpression of the BCRP/MXR/ABCP gene in a topotecanselected ovarian tumor cell line. Cancer Res 59:4559-4563.
32. Nooter K, de la Riviere GB, Klijn J, Stoter G, Foekens J. (1997a). Multidrug resistance protein in recurrent breast cancer. Lancet 349:1885-1886.
33. Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen- Logmans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G, Foekens JA. (1997b). The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76:486-493.
34. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T. (1995). Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72:550-554.
35. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, OGrady J, Robinson C, To Z, Wren K, Banken L, Buhles W, Brown F. (2000). Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44:2811-2815.
36. Potmesil M, Pinedo HM. (1995). Camptothecins: new anticancer agents: CRC.
37. Rozen S, Skaletsky H. (2000). Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365-386.
38. Sawada K, Terada T, Saito H, Hashimoto Y, Inui KI. (1999). Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J Pharmacol Exp Ther 291:705-709.
39. Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. (2005). Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm 2:157-167.
40. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. (1995). Absolute bioavailability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39:2759-2764.
41. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. (2000). Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 89:781-789.
42. Sun Y, Sun J, Shi S, Jing Y, Yin S, Chen Y, Li G, Xu Y, He Z. (2009). Synthesis, transport and pharmacokinetics of 5?-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Mol Pharm 6:315-325.
43. Tsume Y, Hilfinger JM, Amidon GL. (2008a). Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm 5:717-727.
44. Tsume Y, Vig BS, Sun J, Landowski CP, Hilfinger JM, Ramachandran C, Amidon GL. (2008b). Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules 13:1441-1454.
45. Umapathy NS, Ganapathy V, Ganapathy ME. (2004). Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res 21:1303-1310.
46. Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL. (2003). Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 20:1381-1388.
47. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H. (2001). Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514:291-302.